Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Shanghai Junshi Bioscience (1877 HK): Tuoyi Gains Momentum; Losses Narrow; New Geographies Open Up

Shanghai Junshi Bioscience (1877 HK): Placement Good, A Long Term Bet for Sure

Shanghai Junshi Bioscience (1877 HK): Key Drug on High Trajectory; Geopolitical Tension Spoils Party

Equity Bottom-Up

Shanghai Junshi Biosciences  / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-junshi-biosciences-co-838d3eb3-3e0d-45f0-a9c5-ab0764709221" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Shanghai Junshi Biosciences (1877 HK)</a> reported 49% revenue growth on the back of toripalimab during 1H25 in China. 10 indications of total 12 approved, included in China’s NRDL.</li>
<li>Toripalimab (branded as Loqtorzi) in U.S reported ~$17.3M revenue in 1H25 vs $5.8M in 1H24. Approvals received in new geographies like UAE and Kuwait.</li>
<li>With solid R&amp;D focus and Tuoyi’s prospects going ahead, given the regular geographical and indication expansions, it surely offers a long-term growth prospect.</li>
</ul>



Shanghai Junshi Biosciences (1877 HK) reported 49% revenue growth on the back of toripalimab during 1H25 in China. 10 indications of total 12 approved, included in China’s NRDL.
Toripalimab (branded as Loqtorzi) in U.S reported ~$17.3M revenue in 1H25 vs $5.8M in 1H24. Approvals received in new geographies like UAE and Kuwait.
With solid R&amp;D focus and Tuoyi’s prospects going ahead, given the regular geographical and indication expansions, it surely offers a long-term growth prospect.


上海君思生物科技（1877 HK）：トゥオイは堅調な勢いを維持し、上半期の損失は縮小